OUR COMPANY
We are what we do
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab, ZB-168, and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.
OUR PEOPLE
Zura Bio is founded and led by an entrepreneurial management team with broad and deep experience in the pharmaceutical industry and a proven track record of successfully identifying and developing innovative medicines that advance patient care and improve their well-being
Here’s our who’s who
MANAGEMENT TEAM
Robert Lisicki
Chief Executive Officer and Director
Gary Whale, Ph.D.
Chief Technology Officer
Kim Davis
Chief Legal Officer
Kiran Nistala, M.B.B.S., Ph.D.
Chief Medical Officer and Head of Development
Michael Howell, Ph.D.
Chief Scientific Officer and Head of Translational Medicine
Verender Badial
Chief Financial Officer
BOARD OF DIRECTORS
Amit Munshi
Chairman
Arnout Ploos van Amstel
Director
Jen Jarrett
Director
Neil Graham, M.D.
Director
Parvinder Thiara
Director
Robert Lisicki
Chief Executive Officer and Director
Sandeep Kulkarni, M.D.
Director
Someit Sidhu, M.D.
Director
Steve Schoch
Director